INMD Stock Recent News

The latest trading day saw InMode (INMD) settling at $22.54, representing a +0.18% change from its previous close.

InMode (INMD) closed at $22.72 in the latest trading session, marking a -0.09% move from the prior day.

Zacks.com users have recently been watching InMode (INMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Inmode Ltd shares slid more than 12% in pre-market trading on Wednesday after the medical tech company reduced its full-year 2023 guidance, due primarily to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales.  Inmode said it now expects adjusted earnings per share (EPS) for the year of $2.47 to $2.50, down from previous guidance of $2.53 to $2.57.

The stock of InMode Ltd. INMD, -4.33%, an Israeli medical tech company, fell 13% early Wednesday, after the company cut its full-year guidance to reflect stronger-than-expected headwinds from the current macro environment, that was causing a slowdown in platform sales, mainly in North America.

InMode (INMD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

InMode exhibited financial resilience in Q3 2023, with a modest increase in revenue and a significant rise in international sales. The stock price has recently declined but is now consolidating at lower levels, indicating a potential bottoming out. Despite operational challenges, InMode remains optimistic, projecting revenue between $500 million and $510 million for 2023.

InMode Ltd. investors experienced a collapse in October 2023 as INMD fell to a three-year low. I assessed that buyers have returned in November, potentially helping INMD to form a pivotal long-term bottom. InMode's best-in-class profitability and attractive valuation support the constructive buying sentiments.

InMode, known for laser technology in cosmetic applications, faces a blend of market opportunities and financial challenges. INMD's innovative products like Morpheus8 and Evolve drive demand, but geopolitical and economic factors contribute to stock volatility. Financially strong with robust liquid assets and positive cash flow, but faces increased operational costs and margin pressures.

InMode (INMD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.